The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.

BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.

It’s back to school for biotech, with a packed conference schedule.

Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.

Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.